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Abstract
Streptococcus pyogenes infection of the nasopharynx represents a key step in the pathogenic cycle of this organism
and a major focus for vaccine development, requiring robust models to facilitate the screening of potentially
protective antigens. One antigen that may be an important target for vaccination is the chemokine protease, SpyCEP,
which is cell surface-associated and plays a role in pathogenesis. Biophotonic imaging (BPI) can non-invasively
characterize the spatial location and abundance of bioluminescent bacteria in vivo. We have developed a
bioluminescent derivative of a pharyngeal S. pyogenes strain by transformation of an emm75 clinical isolate with the
luxABCDE operon. Evaluation of isogenic recombinant strains in vitro and in vivo confirmed that bioluminescence
conferred a growth deficit that manifests as a fitness cost during infection. Notwithstanding this, bioluminescence
expression permitted non-invasive longitudinal quantitation of S. pyogenes within the murine nasopharynx albeit with
a detection limit corresponding to approximately 105 bacterial colony forming units (CFU) in this region. Vaccination
of mice with heat killed streptococci, or with SpyCEP led to a specific IgG response in the serum. BPI demonstrated
that both vaccine candidates reduced S. pyogenes bioluminescence emission over the course of nasopharyngeal
infection. The work suggests the potential for BPI to be used in the non-invasive longitudinal evaluation of potential S.
pyogenes vaccines.
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Introduction
Streptococcus pyogenes is estimated to be responsible for
over 600 million new cases of pharyngitis each year [1]. In
addition to triggering autoimmune sequelae, such as acute
rheumatic fever, nasopharyngeal infection with S. pyogenes
represents the major reservoir for invasive diseases such as
necrotizing fasciitis, pneumonia and toxic shock syndrome that
together cause an estimated 163,000 deaths worldwide each
year [1].
A number of vaccine candidates are currently in
development for S. pyogenes, although none have yet been
licensed [2]. Many of these are based upon the surface
expressed M-protein [3,4], although antigenic variability is an
obstacle to development [5] coupled with fears regarding
immunological cross-reactivity with human proteins. Some
vaccines focus on more broadly conserved antigens, such as
C5a peptidase [6], fibronectin binding proteins [7,8], or a
combination of bacterial components [9,10].
SpyCEP is known to play a key role in invasive infection,
enabling S. pyogenes to spread systemically [11]. The
mitigation of its effects by vaccination can benefit host survival
after invasive intravenous, intramuscular and lower respiratory
tract infection with S. pyogenes [9,10,12,13]. It is known that
SpyCEP is surface expressed, although the potential of a
SpyCEP-based vaccine to increase bacterial clearance and
confer protection against infection in the nasopharynx has not
yet been evaluated longitudinally.
Biophotonic imaging (BPI) [14] enables the non-invasive
temporal quantification and spatial localization of
bioluminescent bacteria as an infection develops. The
application of longitudinal BPI to such infections can refine in
vivo modelling, and reduce the numbers of animals required for
research [15]. BPI has been used to study the impact of
immunization on longitudinal infection with an emm49 isolate of
S. pyogenes [16] in the context of nasal [6] and peritoneal
infection [4].
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We have previously developed a model of nasopharyngeal
infection using a clinical emm75 S. pyogenes pharyngitis
isolate [17]. Here, we describe the development and evaluation
of a bioluminescent derivative of this clinical S. pyogenes
isolate and the application of BPI to determine the impact of
vaccination on infection of the nasopharynx by S. pyogenes.
Methods
Ethics statement
In vivo experiments were performed in accordance with the
Animals (Scientific Procedures) Act 1986, and were approved
by the Imperial College Ethical Review Process (ERP) panel
and the UK Home Office.
Bacterial strains
Isogenic derivatives of an S. pyogenes emm75 isolate
(H347) were used in all studies. S. pyogenes was cultured on
Columbia Blood Agar (CBA), Todd Hewitt agar (THA), Todd
Hewitt Yeast (THY) broth or C-medium [18]. E. coli strains
DH5α and BL21, used to propagate plasmids and express
protein, were cultured in Luria Bertani (LB) broth.
Plasmids and construction of bioluminescent S.
pyogenes strains
pICL18lux.  The luxABCDE operon was amplified from the
plasmid pSB2025 [19] using primers for the leading sequence
of luxA
(CGCGCCCGGGCCATGGGCAGTCGACAGGAGTCTCTATG
AAATTG) and the closing sequence of luxE
(TTAGAGCTCGCGGCCGCGATATCAACTATCAAACGC).
These were ligated into pUC18N [20] through restriction
digestion with Nco1/Pac1 enzymes (New England Biosciences)
creating pUC18N+luxABCDE. The Phelp promoter sequence
[21] was synthesized by DNA 2.0 in the vector pJ201:19300
and amplified using primers Phelp F
(CGATCTTAGGATCCCCCGGGG) and Phelp R
(TGTAGGTTGGTACCGCGGCCG) then ligated upstream of
luxA in tpUC18N+luxABCDE using NcoI/PacI restriction
digestion. The apha3 kanamycin resistance gene was amplified
from pUCMUT [22] using apha3 F
(TTAATTAAAGCGAACCATTTGAGGTGAT) and apha3 R
(GAGCTCTGGACAGTTGCGGATGTACT) and ligated into this
vector via a PacI/SacI restriction digest. The conserved S.
pyogenes spy0535 gene (accession no. NP_268809) identified
by Park et al [16] as a target of insertion was amplified from S.
pyogenes strain H347 DNA using the Spy F primer
(GAGCTCCAATTAAAAGTTGTGAATTACGAATGA) and Spy
R primer (GGTACCTCCTCACTACTTCTGCCTTTTTG). This
DNA fragment was ligated into the plasmid described above via
a Sac1/Kpn1 restriction digest. The bla ampicillin gene
resistance was excised through restriction digestion with PvuI,
to create pICL18lux (Figure 1A). Loss of the bla ampicillin
resistance gene was confirmed by susceptibility to ampicillin
following successive streaking of pICL18lux-transformed E. coli
onto selective media.
pICL180.  To control for insertion of the plasmid into the
spy0535 region, the luxABCDE operon was excised from
pICL18lux via an EcoRI/BglII restriction digest. Linker primer F
(AATTCGGCGGGACTAGTCGGGGA) and Linker primer R
(GATCTCCCCGACTAGTCCCGCCG) were mixed in equal
molar concentrations within molecular grade water and heated
to 90°C before being cooled to room temperature to produce
an oligonucleotide linker. This linker was inserted into the
plasmid to create pICL180 (Figure 1B).
pTHLK.  To construct a plasmid for multi-copy expression of
the lux operon, plasmid pIB184 [23] was first digested with
ApaI and BamHI, blunted (NEB Blunting Kit) and self-ligated to
remove the P23 promoter. A linear construct comprising the Phelp
promoted luxABCDE operon and aph3a gene was obtained
from pICL18lux and inserted into the unpromoted pIB184
derivative via EcoRI/SacI digestion and ligation to create the
replicating plasmid pTHLK (Figure 1C).
S. pyogenes was transformed with plasmids pICL18lux,
pICL180 and pTHLK by electroporation as described previously
[24] to create the strains H347::lux, H347::0 and H347pTHLK,
respectively. Transformants were selected on agar containing
kanamycin, and screened using bioluminescence where
appropriate. Integration of the pICL18 derived plasmids into the
S. pyogenes chromosome via a single crossover event (Figure
1D) was confirmed using diagnostic primers LF
(CAAAAGATGATGTTGTCCTAATTCA) LR
(GTTTTCCCAGTCACGACGTT), RF
(CCGCAACTGTCCATACTCTG), and RR
(GCTTTTCTATACTATCCCCTTCTTTC) shown in Figure 1 E.
Characterization of bioluminescent strains
Overnight cultures of S. pyogenes strains H347::lux and
H347pTHLK were re-suspended in phosphate buffered saline
(PBS), and tenfold serial dilutions used to quantify
bioluminescence intensity (given as photons s-1) using the
IVIS100 system (PerkinElmer). Bacterial numbers were also
assessed via retrospective plating onto selective agar.
Growth rates of each strain were assessed in THY broth
(n=6 per strain). Bacterial growth was quantified at hourly
intervals by measuring optical density at 600 nm (OD600)
(Biowave, CO 8000 Cell density meter). Luminescence (given
as Relative Light Units [RLU]) was quantified using a Modulus
Single Tube Luminometer (Turner Biosystems).
Stability of bioluminescence expression
The stability of the replicative and integrated plasmids in S.
pyogenes was assessed by serial passage in liquid media. An
inoculum prepared from overnight cultures containing 107
colony forming units (CFU) of either H347pTHLK or H347::lux
was inoculated into THY broth without antibiotic selection
(n=3). Every 24 hours, 1 ml of each culture was inoculated into
49 mls of fresh THY broth with the same growth conditions as
the previous culture. Identical aliquots were taken at regular
intervals over the course of 7 days to quantify the bacteria that
had retained the constructs at each time point, by plating into
THA with and without antibiotic selection.
Bioluminescent S. pyogenes
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Animals
Female 4-5 week old FVB/n mice (Harlan, UK) were
maintained in individually HEPA filtered cages with sterile
bedding and free access to sterilized food and water. GLP Mini
Fun Tunnels (Lillico) were provided in each cage for
environmental enrichment. Mice were weighed daily; reduction
by 20% of original weight was a defined humane endpoint.
In vivo biophotonic imaging
Bioluminescence from infected animals was assessed under
isoflurane anaesthesia using the Xenogen IVIS 100 camera
system (Perkin Elmer). For anatomical localization, a
pseudocolour image representing light intensity (blue, least
intense to red, most intense) was generated using the Living
Image software and superimposed over the grayscale
reference image (displayed as photons s-1 cm-2 sr-1). Images
were gated at a Radiance of 4000 photons s-1 cm-2 steradian
(sr)-1 to eliminate potential background sources of
Figure 1.  Plasmids and integration of pICL18lux into the S. pyogenes chromosome.  The integrating plasmids pICL18lux (A)
and pICL180 (B) and the replicating plasmid construct pTHLK (C) are demonstrated, with arrows indicating locations and
orientations of open reading frames. A diagrammatic representation of the integration of the plasmid pICL18lux into the S. pyogenes
chromosome via a single crossover is shown with the targets for the diagnostic primers LF, LR, RF and RR. Integration will produce
positive results for the regions between LF-LR and RF-RR (D). PCR using these primers was performed on DNA purified from
H347::lux, H347 and the H347::0 (E) and confirmed integration of pICL18lux and pICL180 into the S. pyogenes genome at the
Spy0535 locus.
doi: 10.1371/journal.pone.0082123.g001
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bioluminescence. Total Flux (as photons s-1) within specific
regions of individual mice was also quantified using the region
of interest (ROI) tool in the Living Image software program
(Version 2.0, Perkin Elmer).
Intranasal inoculation
An inoculum of 107 CFU in a 5μl volume was administered to
mice under isoflurane anaesthesia via the intranasal route
using a pipette (2.5μl per nostril). Numbers of viable bacteria
within the inoculum were retrospectively assessed by plating
onto CBA. The nasopharynx was homogenized into PBS and
plated onto CBA to quantify streptococci at the end of each
experiment.
In some experiments, to monitor the intensity of
nasopharyngeal infection longitudinally alongside imaging,
nasal shedding onto CBA was monitored, as a surrogate
marker of intensity of nasopharyngeal infection. Briefly, the
anterior nares were gently applied to CBA plates 10 times and
spread, then plates were incubated overnight and colonies of
bioluminescent S. pyogenes were counted, as previously
described [17]. The presence of S. pyogenes was confirmed by
Gram staining, catalase testing and Lancefield grouping and, in
the case of bioluminescent strains, by luminometry.
In experiments to determine the relation between
bioluminescent signal and bacterial burden in the
nasopharynx, cohorts of mice were infected, then imaged on
day 1, 2, or 3 post infection (n=6 per time point, performed 3
times, n=54). At each time point mice were euthanised and
dissected to obtain nasopharyngeal tissue [17]. This tissue was
then homogenised, plated onto CBA and cultured overnight to
determine the total burden of S. pyogenes.  In a subset of 18
mice (n= 6 per time point, n= 18 total), dissected
nasopharyngeal tissue and nasal associated lymphoid tissue
(NALT) were imaged immediately following dissection, and
then cultured on CBA separately to determine burden of S.
pyogenes in each anatomical location in relation
to bioluminescence.
In vivo competition assay
H347, H347::lux or H347::0 were cultured overnight,
centrifuged (1864×g for 10 min) and washed twice in PBS. The
OD600 for each strain was adjusted to 100 (7×109 CFU ml-1),
and suspensions of different isolates were mixed 1:1 pairwise
and used to inoculate groups of 8 mice. The mixtures were
H347/H347::lux, H347/H347::0 and H347::Lux/H347::0.
Bacterial colonies from the nasopharynx were replica plated
onto selective media on day 1 (4 mice per group) or day 3 (4
mice per group). Individual colonies were inoculated into THY
and bioluminescence quantified after 5 hours of growth
(Modulus Single Tube Luminometer). S. pyogenes that were
either bioluminescent or kanamycin resistant were quantified to
determine the proportion of each strain surviving in vivo.
Competitive Indices (CI) were calculated as follows: CI=(mutant
output/WT output)/(mutant input/WT input).
Vaccination protocol
Mice were immunized intramuscularly with 50μl of vaccine,
comprising either heat-inactivated S. pyogenes strain H347 or
SpyCEP protein, 4, 2 and 1 weeks prior to challenge. To
prepare a heat-killed vaccine, S. pyogenes was heated for 1
hour at 80°C and concentrated to a dose of 108 CFU per
mouse. Sterility was verified by plating onto CBA.
Recombinant CEP (2mg ml-1) was mixed 1:1 with adjuvant to
create the SpyCEP based vaccine [11]. As controls, groups of
mice were immunized either with PBS alone, or with PBS
mixed 1:1 with adjuvant. For priming vaccinations, Complete
Freund's adjuvant was used, and subsequent boosters used
Incomplete Freund's adjuvant, in order to replicate adjuvants
used in a previous vaccination study [12].
Measurement of antibody responses in serum
Murine IgG antibody responses were measured using ELISA
based assays. Plates were coated with 108 CFU ml-1 of heat-
killed S. pyogenes, or 20μg ml-1 of recombinant CEP and
bound IgG selective against these antigens was detected using
HRP-conjugated goat anti-mouse IgG.
Statistics
Regression analysis was used to fit data to the appropriate
linear or logistic models to determine rate constants and to
allow curve comparison. An r2>0.95 was determined to be a
good fit for the data. Differences in bioluminescent signals
between different groups in vivo over time were analysed by
Repeated Measures Two Way ANOVA with Bonferroni
correction. Mann-Whitney analysis was used to analyse
differences in colony numbers between two groups. To analyse
multiple groups, the Kruskal-Wallis test was used. P values
less than 0.05 were determined to be significant. All analyses
were performed using Graphpad Prism (5.0).
Results
Bioluminescence expression by S. pyogenes in vitro
S. pyogenes transformed with either the replicative plasmid
pTHLK (H347pTHLK) or with the integrated pICL18lux construct
(H347::lux) were cultured to logarithmic phase and
luminescence measured. There was a significant difference in
light production between the two bioluminescent strains (Linear
regression p<0.05.). H347pTHLK produced on average 26.19
(± 0.06 SE) photons s-1 CFU-1 whereas H347::lux produced on
average 1.062 (± 0.012 SE) photons s-1 CFU-1 (Figure 2 A).
During passage in vitro, the numbers of S. pyogenes
carrying the pTHLK plasmid (H347pTHLK) declined a
thousand-fold after each passage without antibiotic selection
(Figure 2 B, Repeated measures Two way ANOVA with
Bonferroni correction). In contrast, H347::lux retained the
luxABCDE construct over a seven day period (Figure 2 C),
without the presence of antibiotics. The stability of the
integrated luxABCDE construct made it suitable for further
study.
The expression of bioluminescence impairs growth
The growth characteristics of H347::lux were compared to
both an isogenic strain, H347::0, constructed through
transformation with pICL180, which integrates into the S.
Bioluminescent S. pyogenes
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pyogenes genome at the spy0535 site but does not confer
bioluminescence, and the parental strain H347.
Logistic regression analysis showed no significant difference
in growth rate between the isogenic strains, but H347::lux
demonstrated a significant reduction in the maximum growth
capacity compared with the other strains (Figure 3 A p<0.05).
During growth in vitro, bioluminescence from H347::lux peaked
at 7 h post inoculation (Figure 3 B) and then declined steeply.
This decrease has been previously reported for luxABCDE-
expressing bacteria and reflects a reduction in bacterial
metabolic activity due to the reduced availability of flavin
mononucleotide that is required by the luciferase [25].
The expression of bioluminescence in vivo confers a
competitive disadvantage in the nasopharynx.
Inocula containing pairwise mixes of H347, H347::lux and
H347::0 were administered intranasally (Figure 4 A, n=4 per
group) to determine competitive survival in vivo at day 1 and
day 3 post inoculation. The competitive index relative to the
parental strain was calculated for H347::lux and H347::0 strains
in the nasopharynx (Figure 4 B, Repeated measures Two Way
ANOVA with Bonferroni correction). This showed that H347::lux
was significantly attenuated over the time course compared to
H347::0.
Longitudinal monitoring of intranasal infection with
bioluminescent Streptococcus pyogenes
Intranasal infection caused by H347::lux was studied over
the course of five days using six mice (Figure 5 A). The
luminescent signal dissipated to background levels in the
majority of mice after 4 days of infection, alongside a drop in
bacterial colonies recovered from direct nasal samples (Figure
5 B). Dissections revealed an average of 64228 (±38491 SEM)
CFU of S. pyogenes within the nasopharynx at day 5 post
infection.
The relationship of bioluminescence to bacterial
burden within the nasopharynx
To determine if bioluminescence expressed in the
nasopharynx would correlate with bacterial burden, intranasally
infected mice were culled at days 1, 2 and 3 post inoculation.
Light intensity detected from the dorsal and ventral viewpoints
of the mouse nasopharynx correlated to S. pyogenes
Figure 2.  Characterization of bioluminescent strains in vitro.  Serial dilutions of bioluminescent strains transformed with either
plasmid (H347pTHLK) or integrated construct (H347::lux) were imaged in a 96 well plate (n= 3 separate cultures, Linear regression,
r2>0.95, * p <0.05) using an IVIS 100 system (Perkin Elmer) to relate luminescence to bacterial abundance. Bacteria were quantified
after plating onto agar (A).
H347pTHLK (B) and H347::lux (C) were serially passaged in vitro without antibiotic over 7 days; Samples of each culture were
plated onto kanamycin solid medium or onto non-antibiotic media and demonstrated a failure of H347pTHLK to grow when cultured
on antibiotic containing agar after 72h, consistent with loss of the plasmid. n=3 separate cultures, Repeated measures Two way
ANOVA with Bonferroni correction, * p <0.05). Error Bars indicate median and range.
doi: 10.1371/journal.pone.0082123.g002
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 abundance upon dissection (Figure 6 A, n=54, r2 > 0.95),
demonstrating that bioluminescence can be used to
quantitatively assess carriage. The data revealed a background
signal of 31701 ± 6731 photons s-1 emanating from the
nasopharynx. In practice, this generates a limit of detection of
approximately 5 ×105 CFU when imaging mice from the dorsal
viewpoint.
BPI also revealed the ethmoturbinates to be the primary
anatomical location of S. pyogenes during the first 3 days of
nasal infection (Figure 6 B), and S. pyogenes numbers within
the ethmoturbinate tissue linearly correlated with the signal
Figure 3.  The effect of bioluminescence expression on in vitro growth.  S. pyogenes strain H347::lux was cultured over a 10
hour period alongside the isogenic strains H347 and H347::0. Logistic curves were fitted to the data (A, n=6 per group, from
experiments performed on two separate days, Linear Regression r2>0.95, * p <0.05). Luminescence of H347::lux was quantified
during growth (B) Error bars indicate median and interquartile range.
doi: 10.1371/journal.pone.0082123.g003
Figure 4.  Bioluminescence confers in vivo competitive growth defects.  Mice were infected intranasally using mixed
inoculation paired combinations of H347::lux, H347, and H347::0 as shown. Mice were culled either at day 1 or day 3 post
inoculation and the relative abundance of each strain was assessed through replica plating onto selective media (A, n=4 per group).
These results were used to calculate competitive indices between each mutant strain and the isogenic parent strain H347 (B,
Repeated measures Two way ANOVA with Bonferroni correction * p< 0.05). Error bars indicate median and interquartile range.
doi: 10.1371/journal.pone.0082123.g004
Bioluminescent S. pyogenes
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obtained from mice ex vivo (Figure 6 C, n=18, r2 >0.95). The
signal obtained from the nasal associated lymphoid tissue
(NALT) did not correlate to the detected luminescence (Figure
6 D, n=18) possibly because the burden was too low to be
detected.
Evaluation of heat inactivated S. pyogenes vaccine in a
nasal challenge model using BPI
Following vaccination with heat-inactivated S. pyogenes,
mice were challenged intranasally with H347::lux and imaged
for 4 days post inoculation (Figure 7 A).
Mice immunized with heat-inactivated S. pyogenes emitted
significantly less bioluminescence compared to those
immunized with the PBS control (Figure 7 B, Two-Way ANOVA
p<0.05) and significantly fewer bacteria were present in the
nasopharynx on the final day (Figure 7 C, Mann-Whitney Test
p<0.05). Specific IgG reactive against heat-killed S. pyogenes
was detected in blood samples taken a week before challenge
in vaccinated mice compared with controls (Figure 7 D).
Evaluation of the protective efficacy of SpyCEP vaccine
in a nasal challenge model using BPI
The protective efficacy of a vaccine candidate based on
SpyCEP was then evaluated using the same protocol (Figure
8. A). Extrapolating from bioluminescence data alone, the
SpyCEP vaccine reduced the bioluminescent signal from mice
over the course of the infection compared to control mice
vaccinated with Freund’s Adjuvant (Figure 8 B). However, at
the final time point (Figure 8 C), there was no significant
difference in bacterial numbers within the nasopharynx, when
dissected. Taken together, the data show that SpyCEP
vaccination was not as effective as a vaccine based on a whole
cell vaccination, but do not rule out its use as a component of a
multi-component vaccine.
IgG specific against recombinant CEP were detected in
blood samples taken a week before challenge in vaccinated
mice compared with the Freund’s adjuvant-vaccinated controls
(Figure 8 D).
Discussion
BPI is a technique with great potential for studying infectious
diseases in vivo. In this work, we have developed a new
bioluminescent emm75 pharyngitis strain of S. pyogenes that
can be used to monitor nasopharyngeal infection and have
applied the model to determine the role of SpyCEP as a
component of a vaccine to reduce nasopharyngeal burden.
The clinical strain of S. pyogenes was rendered
bioluminescent through transformation with either a plasmid-
based construct, or through the integration of a single copy of
the luxABCDE operon into the chromosome. Although the
multi-copy plasmid construct conferred greater brightness to S.
pyogenes than the integrating construct, its poor stability
Figure 5.  Imaging of S. pyogenes with a stably integrated lux operon over a time course.  Mice (n=6) intranasally inoculated
with S. pyogenes (H347::lux) were imaged over five days (A, three representative mice shown for each time point) to demonstrate
anatomical localisation. Total flux from the nasopharynx was measured daily alongside longitudinal measurement of S. pyogenes
nasal shedding (B, n=6).
doi: 10.1371/journal.pone.0082123.g005
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without antibiotic selection precluded use in vivo where delivery
of antibiotic would be problematic.
Whilst the expression of luminescence did not significantly
impair the growth rate of S. pyogenes in vitro, survival of the
bioluminescent strains was significantly impaired in vivo
compared with wild type and control strains during
nasopharyngeal infection. In pilot studies, bioluminescent S.
pyogenes reproduced suppurative inflammation in the
nasopharynx similar to that elicited by infection with wildtype
emm75 S. pyogenes at day 3 of infection (data not shown).
However inflammation completely resolved by day 7 in contrast
to previous studies with the parent strain [17], consistent with
reduced longevity and severity of infection.
This reflected a general reduction in competitiveness in the
nasopharynx compared to isogenic strains, which appeared to
be specifically attributable to the lux operon as opposed to any
disruption to the target of insertion. The reactions performed by
the luxAB genes and the luxCDE genes are both energy
intensive, although the latter genes theoretically account for
67% of the energy expenditure in this reaction [26]. We cannot
speculate on which gene(s) of the luxABCDE operon, may
be responsible for the observed fitness burden in S.
pyogenes without disruption of the individual components, and
Figure 6.  Relationship of bioluminescent signal to S.
pyogenes colony counts.  Dorsal and ventral luminescence
measurements obtained in vivo during a three day intranasal
infection were compared to bacterial numbers obtained on
dissection at one, two and three days post infection. (A, Linear
Regression, r2> 0.95, n=54 from three separate experiments
performed on different weeks). The nasopharynx was imaged,
following dissection, to demonstrate anatomical localisation of
the BPI signal.to the posterior turbinates (B).
Bioluminescence of dissected nasal tissue (C) and NALT (D)
was plotted against actual S. pyogenes burden obtained from
these tissues following dissection and culture. Bioluminescent
signal from dissected NALT was plotted against the numbers of
S. pyogenes within nasal tissue and NALT (n=18 each group.
Linear Regression, r2 >0.95 for nasal tissues and, r2 <0.95 for
NALT). Data points shown for individual mice.
doi: 10.1371/journal.pone.0082123.g006
testing in comparison with the bioluminescent strain. These
findings corroborate previous reports, where bioluminescence
has been shown to confer fitness costs in certain situations
[27], and this may limit use of the luxABCDE operon in
research studies aimed at determining subtle phenotypic
differences; other bioluminescence systems may affect fitness
differently .
We have demonstrated that BPI signal intensity in vivo is
proportional to bacterial viable counts, a finding in keeping with
previous studies with different bacteria [4], and providing
further rationale for the use of BPI to reduce animal use by
longitudinal monitoring. In this study we have measured
bioluminescence from a nasopharyngeal focus of infection and
found that flux from the nasopharyngeal region of interest
correlated with CFU. The correlation of bioluminescent flux
(photons s-1) with bacterial counts in vivo was not perfect
however, and is known to be affected by a range of factors
including bacterial growth phase, tissue oxygen tension, use of
anaesthetic drugs, body tissue density, and fur colour [28].
BPI during intranasal infection revealed a peak in the
bioluminescent signal post inoculation, which then fell below
the limit of detection within the majority of mice after five days.
The primary focus of infection in this model was in the
ethmoturbinates, whereas a previous report found NALT to be
the primary focus of infection [16]. Although S. pyogenes were
detected in the NALT, the contrasting findings may be due to
genetic and phenotypic differences between the parental
bacterial strains used [29] or the strain of mouse. In the current
study, an emm75 clinical throat isolate was used for all studies,
while the commercially available bioluminescent emm49 isolate
was derived from strain 591, a skin isolate [30].
During experiments, bioluminescent S. pyogenes produced
an unexpected signal from the genitalia of some mice,
corresponding to infection of the lower vaginal tract, suggesting
direct inoculation through grooming or airborne transmission
within the cage (Figure S1). This underlines the potential for
bacteria used in animal experiments to be transmitted beyond
the intended site of infection and demonstrates the ability of
BPI to identify niches of infection that were not previously
suspected.
Bioluminescent S. pyogenes has previously been used to
determine the protective efficacy of a C5a peptidase based
vaccine against NALT colonization [6]. It has also been used to
evaluate the protective effect of passive immunization against
J8, an M protein derivative, on intraperitoneal infection [4]. In
this study, we used BPI to determine if protective efficacy of
vaccines against S. pyogenes infection in the nasopharynx
could be measured, using SpyCEP as a candidate antigen, and
heat-killed S. pyogenes as a positive control, as a proof of
principle. We observed that the heat-killed S. pyogenes
vaccine significantly reduced streptococcal numbers in the
nasopharynx, as determined by BPI throughout the experiment
and also by viable counts from dissected tissues obtained on
the final day of the study. BPI also demonstrated that a
SpyCEP based vaccine reduced bioluminescence over the
course of infection compared to Freund’s adjuvant alone.
Consistent with BPI data obtained on day 4 however, bacterial
counts in nasal tissues at the end of the study were not
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significantly different between the two groups, although by this
time point, signals were close to the limit of detection. While
less effective than a whole bacterial cell vaccine together with
previous work [9,10,12,13], the data do not rule out use of
conserved components of the cell wall such as SpyCEP as a
part of a multi-component vaccine.
In summary, despite the fitness costs incurred by the
expression of the lux operon, bioluminescent S. pyogenes
Figure 7.  BPI to confirm the protective efficacy of a vaccine based on heat-killed bacteria.  Mice were immunized with either
PBS or with heat-killed S. pyogenes strain H347, and then challenged with intranasal H347::lux. The mice were imaged for 4 days
post infection using an IVIS 100 system (A). Total flux from mice in each group was compared over the time course (B, Repeated
Measures Two way ANOVA with Bonferroni post-test * p<0.05). Colony counts were obtained from dissections performed on the
final day of infection (C, Mann-Whitney, * p<0.05). Serum antibody responses against S. pyogenes from tail bleeds taken before
infection were measured by ELISA (D). Error bars indicate mean and SD.
doi: 10.1371/journal.pone.0082123.g007
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PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e82123
 provide a useful model for short term infection monitoring in
the nasopharynx and could be used to rapidly and non-
invasively screen for S. pyogenes vaccine efficacy.
Supporting Information
Figure S1.  Colonisation of the Genitalia with
bioluminescent S. pyogenes during intranasal infection.
Mice intranasally infected with S. pyogenes occasionally
Figure 8.  BPI to determine protective efficacy of a vaccine based on SpyCEP.  Mice were immunized with either Freund’s
adjuvant, or SpyCEP + Freund’s adjuvant, and then challenged with H347::lux. The mice were imaged for 4 days post infection
using an IVIS 100 system (A). Total flux from mice in each group was compared over the time course (B, Repeated measures Two
way ANOVA with Bonferroni correction, * p<0.05) Colony counts were obtained from dissections performed on the final day of
infection (C). Serum antibody responses against SpyCEP from tail bleeds taken before infections were measured by ELISA (D)
Error bars indicate mean and SD.
doi: 10.1371/journal.pone.0082123.g008
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produced a bioluminescent signal from their genitalia during
time course experiments.
(TIF)
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